Rigel Pharmaceuticals (NASDAQ: RIGL) CFO Schorno reports 5,488-share disposal

Rhea-AI Filing Summary

Rigel Pharmaceuticals executive Dean L. Schorno, EVP & Chief Financial Officer, reported a Form 4 transaction involving company common stock. On 02/02/2026, 5,488 shares of common stock were disposed of in a transaction coded "F" at a price of $36.01 per share.

Following this transaction, Schorno beneficially owned 59,247 shares of Rigel common stock in direct ownership. This total includes 500 shares acquired under Rigel’s stock purchase plan, as noted in the filing’s footnote.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schorno Dean L

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		F		5,488	D	$36.01	59,247(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 500 shares acquired under the Issuer's stock purchase plan.

	/s/ Raymond Furey (Attorney-in-Fact)	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rigel (RIGL) report for Dean L. Schorno?

Rigel reported that EVP & Chief Financial Officer Dean L. Schorno disposed of 5,488 shares of common stock on 02/02/2026 at $36.01 per share in a transaction coded “F,” according to the Form 4 filing.

How many Rigel (RIGL) shares does Dean L. Schorno own after the reported transaction?

After the 02/02/2026 transaction, Dean L. Schorno beneficially owned 59,247 shares of Rigel common stock. The filing indicates this amount is held in direct ownership following the disposal of 5,488 shares reported on the Form 4.

What does transaction code "F" mean in Dean L. Schorno’s Rigel (RIGL) Form 4?

The Form 4 lists the transaction for 5,488 shares as code “F”, with the shares shown as disposed of at $36.01 per share. The filing identifies this as a non-derivative common stock transaction involving Rigel Pharmaceuticals.

What role does Dean L. Schorno hold at Rigel Pharmaceuticals (RIGL)?

Dean L. Schorno is identified as Executive Vice President & Chief Financial Officer of Rigel Pharmaceuticals, Inc. in the Form 4. He is not listed as a director or 10% owner, but as an officer with this specific title.

Does Dean L. Schorno’s Rigel (RIGL) share total include stock purchase plan shares?

Yes. A footnote states that the beneficial ownership figure of 59,247 shares for Dean L. Schorno includes 500 shares acquired under Rigel’s stock purchase plan, clarifying the composition of his reported holdings.

Was Dean L. Schorno’s Rigel (RIGL) transaction direct or indirect ownership?

The Form 4 shows direct ownership (D) for both the 5,488 shares disposed of and the 59,247 shares beneficially owned after the transaction, with no indirect ownership nature specified in the filing.